Table 1.
Effects of MPG, APO, and l-NAME on basal contractility, relaxation, and MAP duration
| LVDP, mmHg | +dP/dt, mmHg/s | t1/2, ms | MAPD90, ms | |
|---|---|---|---|---|
| Control | 84.6 ± 7.4 | 2761.3 ± 238.5 | 48.8 ± 1.9 | 51.8 ± 5.8 |
| MPG (n = 8) | 92.7 ± 12.3 | 2560.0 ± 144.8 | 54.6 ± 2.8 | 52.5 ± 2.8 |
| Control | 88.8 ± 3.3 | 2696.6 ± 128.3 | 48.4 ± 0.8 | 50.6 ± 6.9 |
| APO (n = 6) | 90.1 ± 5.6 | 2686.7 ± 155.9 | 53.9 ± 2.2 | 55.8 ± 0.7 |
| Control | 96.2 ± 8.0 | 3340.3 ± 243.5 | 49.8 ± 3.9 | 56.0 ± 1.5 |
| l-NAME (n = 9) | 97.5 ± 6.0 | 3389.7 ± 203.4 | 55.8 ± 5.3 | 57.0 ± 0.6 |
Values are means ± SE and were obtained at the end of the stabilization (Control) and at the end of the 10-min period of drug perfusion, prior to ischemia. LVDP, left ventricular developed pressure; +dP/dt, maximal rate of pressure development; t1/2, half relaxation time; MAPD90, monophasic action potential duration at 90% repolarization; MPG, mercaptopropionylglycine; APO, apocynin; l-NAME, NG-nitro-l-arginine methyl ester.